ClinicalTrials.gg
RecruitingNCT07413757CHOICEUpdated Oct 9, 2026

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

An observational study in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
590
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 26 open to participants now, 79 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Planned enrollment
23rd of 67
590 · median 350
Started
2026
with 8 others
Observational
67 of 210
10 open now
Primary completion
2026-11
later than 38 of 78 live
Registered
205th of 210
by date

Among the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 23rd largest by planned enrollment of the 67 observational ones that give a count, is one of 9 that started in 2026, is one of 67 observational ones, reaches primary completion later than 38 of the 78 other live ones, and was the 205th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

26 of the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

Read the detailed description

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

The study will collect data from participants via the questionnaire developed by the research team. This study will be conducted in two stages. Stage 1 is the study design phase (i.e., qualitative stage and questionnaire development), which includes the development of the questionnaire, identification of key attributes and levels for the Discrete Choice Experiment (DCE), creation of hypothetical patient profiles to explore high-risk factors in physician decision-making beyond the DCE, as well as questionnaire programming, internal review, pilot testing, revisions, and finalization. Stage 2 involves the implementation of the quantitative survey using the finalized questionnaire and the subsequent data analysis to generate insights into treatment preferences.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • NSCLC;patients and physicians;survey;EGFR-TKI;patient preference;physician preference
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will include patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC and physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI. To improve the sample representativeness and generalizability, some soft quotas may be applied during sampling. All the participants who met inclusion criteria will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following inclusion criteria must be met in order to be enrolled in the stage 1:

Patient:

  • Provide
  • 18 years or older
  • Diagnosed with stage IV NSCLC
  • Currently receiving or previously received 1L EGFR-TKI treatment
  • Without communication barrier
  • Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter

Physician:

  • Provide informed consent
  • Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
  • Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
  • Holding the title of associate chief physician or higher

The following inclusion criteria must be met in order to be enrolled in the stage 2:

Patient:

  • Provide informed consent
  • 18 years or older
  • Diagnosed with stage IV NSCLC
  • Currently receiving or previously received 1L EGFR-TKI treatment
  • Without communication barrier
  • Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter

Physician:

  • Provide informed consent
  • Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
  • Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
  • Holding the title of attending physician or higher

Exclusion criteria

Exclusion Criteria:

Not applicable.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
590 participants (estimated)
Patient registry
No

Groups and cohorts

  • Physicians group

    Physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI.

  • Patinet group

    Patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC

06

What researchers measure

Primary outcomes

  1. Preferences weights for each attribute level evaluated in the DCE

    Preference weights will be estimated for each attribute level included in the DCE where a more positive preference weight indicates a stronger preference for the attribute level. The preference weights allow for comparison for relative preference for levels within the same attribute.

    Time frame: Day of interview/survey completion(Day1)

  2. Relative attribute importance (RAI)

    The importance measure will be used to evaluate the preferences among treatment attributes. This measure will be calculated by using the difference of utility scores between the most and least preferred levels within an attribute. Then, this measure will divide by the summation of the difference of all tested attributes.

    Time frame: Day of interview/survey completion(Day1)

Secondary outcomes

  1. Maximum acceptable risks (MAR) and minimum acceptable benefit (MAB)

    This measure will be used to evaluate the trade-offs participants are willing to make between an improvement in a pre-defined attribute related to efficiency (such as PFS) compared to a worsening in each AE relevant attribute (such as rash). * MAR quantifies the average maximum level of risk factors (e.g., incidence of rash, incidence of diarrhea, etc.) that participants are willing to tolerate in exchange for a specified improvement in clinical outcomes. * MAB represents the minimum level of benefit required to justify an increase in risk. It is derived from the marginal rate of substitution (MRS) between risk and benefit attributes, calculated using the estimated preference weights from the DCE model.

    Time frame: Day of interview/survey completion(Day1)

  2. RAI, MAR, and MAB by patient and physician characteristics subgroups

    * RAI quantifies the relative weight participants place on each attribute (e.g., efficacy vs. side effects) in their decision-making. * MAR and MAB will be estimated separately for subgroups defined by patient (e.g., age, gender, with/without central nervous system \[CNS\] metastasis) and physician (e.g., title, years of experience) characteristics.

    Time frame: Day of interview/survey completion(Day1)

  3. Odds ratios (ORs) for the association between patient characteristics and the likelihood of physicians recommending combination therapy (EGFR-TKI plus platinum/pemetrexed chemotherapy or EGFR-TKI plus bispecific antibody) versus EGFR-TKI monotherapy

    o OR quantifies changes in the likelihood of physicians recommending combination therapy over monotherapy, depending on the presence or absence of specific patient characteristics (e.g., age, CNS metastases, high tumor burden). An OR \> 1 indicates an increased likelihood of recommending combination therapy for patients with the characteristic, while an OR \< 1 indicates a decreased likelihood.

    Time frame: Day of interview/survey completion(Day1)

07

Study locations

1 of 1 sites recruiting
  • Research Site
    Chengdu, 610000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Nov 12, 2026
CompletionEst.
Nov 12, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07413757
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Mar 2, 2026
Primary completion
Nov 12, 2026 (estimated)
Completion
Nov 12, 2026 (estimated)
Last update
Oct 9, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion